ArticleBMC cancer2026
Anti-BNLF2b antibody for accurate diagnosis of nasopharyngeal carcinoma: a prospective comparative study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNasopharyngeal carcinoma (NPC) is highly prevalent in Southern China and Southeast Asia and early detection significantly improves prognosis. Conventional Epstein-Barr virus (EBV) serological markers VCA-IgA and EBNA1-IgA have been widely used for NPC screening yet their performance remains unsatisfactory in real-world screening scenarios. Anti-BNLF2b antibody (P85-Ab) has emerged as a promising novel serological biomarker. However, comprehensive comparisons with conventional markers in clinically diverse cohorts incorporating diverse non-NPC patients remain insufficiently evaluated.
methodsA prospective case-control study was performed, recruiting 122 NPC patients and 185 control subjects (99 healthy individuals and 86 patients with non-NPC disorders). Six serological EBV antibody biomarkers were evaluated: Wantai_P85-Ab, Wantai_EBNA1-IgA, Wantai_VCA-IgA, Snibe_VCA-IgA, Wantai_Zta-IgA, and Tarcine_Rta-IgG. Propensity score matching (PSM) was implemented to balance demographic covariates between NPC cases and controls. Receiver operating characteristic (ROC) curve analysis was adopted to calculate the area under curve (AUC), sensitivity and specificity for evaluating diagnostic accuracy, and concordance analysis was conducted to explore the complement value of distinct biomarkers.
resultsAfter PSM, the matched analytical cohort contained 244 participants (122 NPC cases, 122 controls). Wantai_P85-Ab achieved an AUC of 0.989 (95% CI: 0.966-0.998), which was significantly higher than Wantai_EBNA1-IgA (0.942, 95% CI: 0.904-0.967), Wantai_VCA-IgA (0.874, 95% CI: 0.826-0.913), Wantai_Zta-IgA (0.847, 95% CI: 0.796-0.890), Tarcine_Rta-IgG (0.774, 95% CI: 0.716-0.824), and Snibe_VCA-IgA (0.601, 95% CI: 0.536-0.663) (all P < 0.001). Wantai_P85-Ab achieved a sensitivity of 94.26% (95% CI: 88.63-97.19) and specificity of 98.36% (95% CI: 94.22-99.55). Subgroup specificity analysis showed P85-Ab reached 100.00% (95% CI: 96.26-100.00) when distinguishing NPC from healthy controls, and 95.35% (95% CI: 88.64-98.18) against non-NPC disease patients. Furthermore, Wantai_P85-Ab exhibited comparable sensitivity in early-stage (n = 20) NPC (95.00%, 95% CI: 76.39-99.11) and advanced-stage (n = 102) NPC (94.12%, 95% CI: 87.76-97.28). Parallel combination of Wantai_P85-Ab and Wantai_EBNA1-IgA modestly increased sensitivity to 97.54% (95% CI: 93.02-99.16) with a significant declined specificity of 92.62% (95% CI: 86.57-96.07).
conclusionsThis prospective comparative study with mixed clinical controls indicates that Wantai_P85-Ab has potential advantages over conventional single EBV serological markers. These findings provide supplementary clinical evidence supporting the application of P85-Ab as a primary serological biomarker for NPC screening and auxiliary diagnosis in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.